ArticleHaematologica2019
Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target.
Abstract read
In one paragraph
Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.Leukemia · 2026Trial
- A phase I/II study of tagraxofusp in Japanese patients with blastic plasmacytoid dendritic cell neoplasm.International journal of hematology · 2026Trial
- Article
- Article
- Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience.Oncotarget · 2025Article
- Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN.Blood neoplasia · 2025Article
- Review
- Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base.Leukemia research reports · 2025Article
- Diagnostic approach to blastic plasmacytoid dendritic cell neoplasm: historical perspectives and current understanding.Journal of clinical and experimental hematopathology : JCEH · 2025Review
- BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia.JCI insight · 2024Article
- Genome-wide DNA methylation-analysis of blastic plasmacytoid dendritic cell neoplasm identifies distinct molecular features.Leukemia · 2024Article
- Simultaneous blastic plasmacytoid dendritic cell neoplasm and myelofibrosis: A case report.Oncology letters · 2024Article
- TET2 mutation as prototypic clonal hematopoiesis lesion.Seminars in hematology · 2024Review
- [Blastic plasmacytoid dendritic cell tumor treated with DVT regimen: a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Review
- Venetoclax combined with azacitidine in blastic plasmacytoid dendritic cell neoplasm: a case report and comprehensive review on the current and future treatment.Frontiers in medicine · 2024Article
- Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview.Hematology reports · 2023Review
- Article
- Article
- Top Ten Lymphoproliferative Lesions Not to Miss When Evaluating Oral Ulcer Biopsies.Head and neck pathology · 2023Review
- SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities.Molecular cancer · 2023Review
Corrections and comments
- Commented on by
Authors and funding
31 authors.
Maria Rosaria SapienzaHematopathology Unit, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Italy mariarosaria.sapienza@gmail.com.
Francesco AbateDepartment of Systems Biology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Federica MelleDivision of Haematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Stefania OrecchioniLaboratory of Hematology-Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Fabio FuligniDepartment of Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada.
Maryam EtebariHematopathology Unit, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Italy.
Valentina TabanelliDivision of Haematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Maria Antonella LaginestraHematopathology Unit, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Italy.
Alessandro PileriDermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy.
Giovanna MottaDivision of Haematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Maura RossiHematopathology Unit, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Italy.
Claudio AgostinelliHematopathology Unit, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Italy.
Elena SabattiniHematopathology Unit, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Italy.
Nicola PimpinelliDivision of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Italy.
Mauro TruniPathological Anatomy Histology & Cytogenetics, Niguarda Cancer Center, Niguarda-Ca' Granda Hospital, Milan, Italy.
Brunangelo FaliniInstitute of Hematology and Center for Hemato-Oncology Research (CREO), University and Hospital of Perugia, Italy.
Lorenzo CerroniUniversitätsklinik für Dermatologie und Venerologie, LKH-Universitatsklinikum Graz, Austria.
Giovanna TalaricoLaboratory of Hematology-Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Rossana PiccioniDepartment of Experimental Oncology, European Institute of Oncology, Milan, Italy.
Stefano AmenteDepartment of Molecular Medicine and Medical Biotechnologies, University of Naples 'Federico II', Italy.
Valentina Indio"Giorgio Prodi" Cancer Research Center, University of Bologna, Italy.
Giuseppe Tarantino"Giorgio Prodi" Cancer Research Center, University of Bologna, Italy.
Francesco BrunduDepartment of Systems Biology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Marco PaulliUnit of Anatomic Pathology, Department of Molecular Medicine, University of Pavia and Fondazione IRCCS San Matteo Policlinic, Pavia, Italy.
Emilio BertiDepartment of Dermatology, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinic and Milan University, Milan, Italy.
Fabio FacchettiPathology Section, Department of Molecular and Translational Medicine, University of Brescia, Italy.
Gaetano Ivan DellinoDepartment of Experimental Oncology, European Institute of Oncology, Milan, Italy.
Francesco BertoliniLaboratory of Hematology-Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Claudio TripodoTumor Immunology Unit, Department of Health Science, Human Pathology Section, University of Palermo School of Medicine, Italy.
Raul RabadanDepartment of Systems Biology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Stefano A PileriDivision of Haematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy for which there is still no effective therapy. In order to identify genetic alterations useful for a new treatment design, we used whole-exome sequencing to analyze 14 BPDCN patients and the patient-derived CAL-1 cell line. The functional enrichment analysis of mutational data reported the epigenetic regulatory program to be the most significantly undermined (
Indexed as
Hematologic NeoplasmsMyeloproliferative DisordersNeoplasm ProteinsSkin NeoplasmsAgedAnimalsAzacitidineCell Line, TumorDecitabineEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, Inbred NODAzacitidineDecitabineNeoplasm Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.